Sign up Australia
Proactive Investors - Run By Investors For Investors

Midatech Pharma trading in line with forecasts with focus turning to clinical trials

The three studies will be closely monitored by investors
results graphic
The trading update showed revenues were going in the the right direction, while Midatech said its US arm broke even in the second-half

Midatech Pharma Plc (LON:MTPH, NASDAQ:MTP) said trading last year was in line with forecasts with the focus in 2018 turning to three key clinical trials.

A first in-human study of Q-Octreotide, for the treatment carcinoid cancer and the hormonal disorder acromegaly, is expected to complete late this year or early next year.

READ: Critical year ahead of drug development for Midatech Pharma

A clinical assessment of MTX110, an investigational nano-inclusion product for the treatment of the fatal childhood brain cancer, Diffuse Intrinsic Pontine Glioma (DIPG), is expected to read out towards the end of 2019. 

Phase IV trial

Midetech is also carrying out a phase IV trial of cancer care product Gelclair that could expand its addressable market. This will assess its use in stem cell patients suffering oral mucositis, a side-effect of the treatment.

Unlike many other drug development companies the nano-technology specialist has a revenue-generating commercial operation which sells four cancer care support products.

In an update on its trading, the firm said turnover for 2017 would likely be in the order of £7.4mln, up from £6.9mln and in line with market forecasts. US product sales are expected to be up by 29% at £6.7mln. Midatech said the American unit reached  break-even in the second-half.

Net cash balance December 2017 31 was £13.2m – also in line with forecasts.

View full MTPH profile View Profile

Midatech Pharma Plc Timeline

Related Articles

1514990464_biotech_517925923.jpg
January 04 2018
Investors have been cheered by the method used to raise fresh investment, which avoids the need to issue more shares for cash
woman at a microscope
September 04 2017
Lead product Lojuxta generated revenues of €5.75mln in the first-half

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use